StemCell Therapy

This is true on all fronts.  Cancer immunotherapy conferences are popping up everywhere.  A growing number of of analysts are now covering a growing number of companies in the space with coverage ranging from bearishly critical to ebullient bullishness. Some venture capital firms are now loosening their purse strings for immunotherapy plays and both pharma venture funds and business development departments are now spending an increasing amount of time actively monitoring and exploring potential plays in the sector.

• Argos Therapeutics' AGS-003
• phase III trial not yet recruiting
• Indication: advanced renal cell carcinoma
• Estimated enrollment: 450
• Estimated primary completion: June 2014 

• Cell Medica's Adoptive Cellular Therapy (ACT) 
• phase III trial actively recruiting
• Indication: cytomegalovirus infection following allogeneic stem cell transplantion
• Estimated enrollment: 90
• Estimated primary completion: June 2013

• JW Creagene's CreaVax-RCC 
• phase III trial actively recruiting
• Indication: metastatic renal cell carcinoma
• Estimated enrollment: 54
• Estimated primary completion: unknown

• Kiadis Pharma's alloreactive T-cells (ATIR)
• phase II/III trial currently suspended
• Indication: infections and relapse assoc’d w/ SCT for leukemia and other hematologic malignancies
• Estimated enrollment: 70
• Estimated primary completion: TBD

• MolMed's TK
• phase III trial actively recruiting
• Indication: acute leukemia
• Estimated enrollment: 170
• Estimated primary completion: January 2014

• Newlink Genetics' HyperAcute®-Pancreas (algenpantucel-L)
• phase III trial actively recruiting
• Indication: pancreatic cancer
• Estimated enrollment: 722
• Estimated primary completion: January 2014

• NovaRx's Lucanix
• phase III trial actively recruiting
• Indication: non-small cell lung cancer
• Estimated enrollment: 506
• Estimated primary completion: June 2012

• PrimaBioMed's Cvac
• phase II/III trial actively recruiting
• Indication: epithelial ovarian cancer
• Estimated enrollment: 1,000
• Estimated primary completion: March 2015

Phase II or I/II

• 50 industry-sponsored clinical trials of cell-based immunotherapies actively recruiting, active no longer recruiting, active not yet recruiting, or anticipated to commence yet in 2012
• ~10 of these are expected to have readouts yet this year
• Trial sites in US, Canada, UK, continental Europe, Israel, South Korea, India, Australia
• Expected enrollment of 3,500+

-- Lee @celltherapy

p.s.  As always we welcome your feedback, comments, and corrections.